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Age‐related macular degeneration (AMD) associated with dysfunction of retinal pigment
epithelial (RPE) cells is the most common cause of untreatable blindness. To advance
gene therapy as a viable treatment for AMD there is a need for technologies that enable
controlled, RPE‐specific expression of therapeutic genes. Here we describe design, con-
struction and testing of compact synthetic promoters with a pre‐defined transcriptional
activity and RPE cell specificity. Initial comparative informatic analyses of RPE and
photoreceptor (PR) cell transcriptomic data identified conserved and overrepresented
transcription factor regulatory elements (TFREs, 8–19bp) specifically associated with
transcriptionally active RPE genes. Both RPE‐specific TFREs and those derived from the
generically active cytomegalovirus‐immediate early (CMV‐IE) promoter were then
screened in vitro to identify sequence elements able to control recombinant gene tran-
scription in model induced pluripotent stem (iPS)‐derived and primary human RPE cells.
Two libraries of heterotypic synthetic promoters varying in predicted RPE specificity and
transcriptional activity were designed de novo using combinations of up to 20 discrete
TFREs in series (323–602bp) and their transcriptional activity in model RPE cells was
compared to that of the endogenous BEST1 promoter (661 bp, plus an engineered
derivative) and the highly active generic CMV‐IE promoter (650bp). Synthetic promoters
with a highpredicted specificity, comprised predominantly of endogenous TFREs
exhibited a range of activities up to 8‐fold that of the RPE‐specific BEST1 gene promoter.
Moreover, albeit at a lower predicted specificity, synthetic promoter transcriptional
activity in model RPE cells was enhanced beyond that of the CMV‐IE promoter when
viral elements were utilized in combination with endogenous RPE‐specific TFREs, with a
reduction in promoter size of 15%. Taken together, while our data reveal an inverse
relationship between synthetic promoter activity and cell‐type specificity, cell context‐
specific control of recombinant gene transcriptional activity may be achievable.
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1 | INTRODUCTION
The retinal pigment epithelium (RPE) is a multifunctional monolayer
of neuroepithelium‐derived cells, flanked by photoreceptor (PR) cells
and the choroid complex. The significance of the RPE in the ocular
system is exemplified by the major association of these pigmented
cells in genetically determined retinal diseases such as age‐related
macular degeneration and retinitis pigmentosa. Accordingly, various
in vitro human RPE models have been established as a convenient
platform to study RPE functions, where the two most commonly
used models are primary human fetal RPE cells and immortalized cell
lines such as ARPE‐19 and hRPE7. Nonetheless, studies of their
morphologic and functional characteristics have produced contra-
dictory results (Ablonczy et al., 2011) demonstrating the limitation of
immortalized cells in studying native human RPE function. The more
recent discovery of induced pluripotent stem (iPS) cells has also
yielded iPS‐derived RPE cells that closely mimic the gene expression,
polarity, and physiology of native human RPE cells (Kokkinaki
et al., 2011; Liao et al., 2010). However, despite a significant amount
of research on global gene expression profiling of stem‐cell‐derived/
primary RPE cells and native tissue, there are no methods to sys-
tematically link transcriptomic data sets with genomic data to iden-
tify cis‐regulatory elements that would provide inherently RPE‐
specific expression of recombinant genes.
The recent approval of voretigene neparvovec (Luxturna®) to
treat retinal degeneration highlights that gene therapies to disease‐
causing genetic mutations are possible. This achievement is partly
made possible by the use of adeno‐associated viral (AAV) vectors
that can transduce and maintain therapeutic gene expression in non‐
dividing cells (including the retina) with minimal immune responses
(Naso et al., 2017). Ubiquitous promoters such as that derived from
human cytomegalovirus (CMV) are often used to drive high trans-
gene expression despite potentially undesirable attributes such as
promoter silencing and lack of cell‐type specificity. Endogenous
promoters, on the other hand, often have lower activity compared to
viral‐derived promoters and are a relatively large size, thus limiting
their use in viral vectors. For example, the ~1.6 kb‐long RPE65
promoter displayed only 10% of CMV activity when used to induce
targeted expression of the RPE65 gene in RPE65‐deficient canines,
and was inactive in older animals (Le Meur et al., 2007). The latter
illustrates a further possible constraint in the use of endogenous cell‐
specific promoters in which their expression may be downregulated
for target tissues that are already in a state of disease. Similarly,
Komáromy et al. (2010) also reported (endogenous) promoter length
and age dependency, where the long version of the red cone opsin
promoter (~2.1 kb) in younger animals led to a more stable ther-
apeutic effect for achromatopsia. In this context, bespoke synthetic
promoters are an attractive alternative as they can be custom‐
designed to control recombinant gene expression predictably in a
specific cellular context.
A number of studies report engineering of natural promoters for
improved activity in a therapeutic context. Examples include the
creation of hybrid promoters to selectively kill cancerous tissues via
incorporation of the prostate‐specific probasin promoter into the
retroviral LTR to target prostate cancer cells (Logg et al., 2002) or by
coupling the endothelin enhancer element with the Cdc6 promoter
to target dividing tumor endothelial cells (Szymanski et al., 2006).
More advanced attempts to create promoters with increased tissue‐
specificity are exemplified via de novo design of synthetic promoters
that could specifically mediate gene expression in muscle cells
(Li et al., 1999), colorectal cancer cells (Roberts et al., 2017) or liver
cells with responsiveness to glucose (Han et al., 2011). However,
these studies involved screening hundreds to thousands of synthetic
promoters, which is unfeasible for primary and iPS‐derived cells, such
as RPE, with a limited capacity for expansion and which exhibit a
particular differentiated morphological state. Further, there remains
no information on how it is possible to utilize RPE model cells in vitro
to characterize the function of individual genetic components to
eliminate uncontrollable and functionally ill‐defined parts of en-
dogenous promoter assemblies.
In this study, we test the hypothesis that RPE genomic in-
formation can be mined to identify active transcription factor reg-
ulatory elements (TFREs) that could be utilized to design compact,
space‐efficient synthetic promoter assemblies that exhibit both a
high degree of cell type specificity and transcriptional activity.
Through systematic bioinformatic analysis of ‘omic data streams
coupled with in vitro screening we identified endogenous human
TFRE sequences that are potentially active in the different eye
components (i.e., RPE vs. PR) as well as those that function as
transcriptional repressors. We further identified highly active TFREs
present in the human CMV promoter that enable active and space‐
efficient synthetic promoter constructs that recruit RPE cell intrinsic
transcriptional capacity. Based on these data, we designed RPE‐
active promoter/TFRE assemblies de novo with different objective
functions, either high RPE specificity (no, or low transcriptional ac-
tivity in PR cells) and/or high RPE transcriptional activity. We also
compared the de novo (bottom‐up) synthetic promoter design
strategy to (top‐down) targeted re‐engineering of the RPE‐specific
bestrophin‐1 (BEST1) promoter for improved activity in RPE cells.
While this study demonstrates effective construction of promoters
for RPE cells, similar approaches could be used to design promoters
for applications requiring specific and/or high expression of
recombinant genes in other cell types.
2 | MATERIALS AND METHODS
2.1 | iPS‐derived and primary human RPE cell
cultures
Cryopreserved iPS‐derived human RPE cells (iCell® RPE) were
obtained from FujiFilm Cellular Dynamics and cultured according
to the manufacturer's instructions using MEMα (Thermo Fisher
Scientific) supplemented with KnockOut SR (Thermo Fisher
Scientific), N‐2 supplement (Thermo Fisher Scientific), hydro-
cortisone (Sigma), taurine (Sigma), triiodo‐L‐thyronine (Sigma) and
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gentamicin (Thermo Fisher Scientific). Cryopreserved human fetal
RPE cells (Clonetics® RPE) were obtained from Lonza and cultured
according to the manufacturer's instructions using RtEGM RPE
Cell Growth Medium BulletKit (Lonza) and ReagentPack sub-
culture reagents (Lonza). iPS‐derived cells were maintained in
vitronectin‐coated vessels and primary cells were maintained in
tissue culture‐treated vessels at 37°C under 5% CO2 in humidified
incubator. Cell concentration and viability were measured using a
Vi‐CELL XR (Beckman Coulter).
2.2 | In silico analysis of TFREs
RPE and PR microarray data were obtained from the literature (Booij
et al., 2009, 2010; Table S1). For each gene, 2000 bp upstream of the
start codon was extracted from human genome database GRCh38/
hg38. Transcriptional start sites (TSSs) were determined based
on the literature, Eukaryotic Promoter Database (EPD; epd.epfl.ch)
or annotated 5′‐UTRs. Genomatix Gene Regulation software
(MatInspector Release 8.2 and MatBase Version 9.4; Genomatix) was
used to analyze the region ‒1000 to +200 relative to the TSS (or up
to the start codon) to find putative TFREs. Overrepresented TFREs
were identified by analyzing the promoters against Genomatix‐
defined human promoter background followed by selection of the
TFREs with Z‐score > 2.5, whereas common TFREs were identified
using core similarity of 1.0 and optimized matrix similarity of +0.01
followed by selection of the TFREs with p > .2 against Genomatix‐
defined randomly drawn promoter samples. Identification of TFREs
in hCMV‐IE promoter using MatInspector was performed using core
similarity of 0.75 and optimized matrix similarity.
2.3 | TFRE‐reporter vector construction
pmaxGFP vector (Lonza) was utilized as a backbone. The CMV pro-
moter and chimeric intron of pmaxGFP were deleted by digestion with
BsrGI and KpnI, and replaced with a short DNA fragment containing a
HindIII site. A minimal CMV core promoter from the human CMV was
synthesized (Eurofins Genomics), PCR amplified (Q5 high‐fidelity
2×master mix; NEB), and purified (QIAquick PCR Purification Kit;
Qiagen). The PCR products were then digested with HindIII and KpnI
enzymes (NEB), gel extracted (QIAquick Gel Extraction Kit; Qiagen)
and inserted directly upstream of the green fluorescent protein (GFP)
open reading frame (ORF) of the promoterless pmaxGFP vector. The
CMV core promoter sequence used was as follows: 5′‐AGGTCTAT
ATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGC
CATCCACGCTGTTTTGACCTCCATAGAAGAC‐3′. To create TFRE
reporter plasmids, synthetic oligonucleotides containing 7× repeat
copies of the TFRE sequences in Tables 1 and 2 were synthesized,
PCR amplified, and inserted into BsrGI and HindIII sites upstream of
the CMV core promoter. Clonally derived plasmids were purified using
a QIAGEN Plasmid Plus kit (Qiagen). The sequence of all plasmid
constructs was confirmed by DNA sequencing.
2.4 | Synthetic promoter vector construction
To create synthetic promoters, synthetic genes containing combi-
nations of specific TFREs were designed in silico (Tables 3 and 4).
The positions of the TFRE blocks within the promoters were ran-
domly arranged using R software in forward orientation of 5′ DNA
strand. Synthetic genes were synthesized (Eurofins Genomics) and
inserted into BsrGI and HindIII sites upstream of the CMV core
promoter. A full length CMV promoter containing the same CMV
core (‒600 to +50 relative to the TSS) and endogenous BEST1 pro-
moter (‒585 to +76 relative to the TSS) were also synthesized and
inserted separately into BsrGI and KpnI sites upstream of the GFP
ORF. The sequence of all plasmid constructs was confirmed by DNA
sequencing. The estimated RPE/PR specificity ratio of a promoter
was calculated as follows:
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= ∑ × ×∑ × × (1)
where Ta is the transcriptional activity of a specific TFRE, i is a
specific TFRE type, N is the copy number of a specific TFRE in the
promoter, and mRNARPE/PR is the cognate TF mRNA expression fold‐
change in RPE over PR (derived from Booij et al., 2010; Table S2).
2.5 | Transient transfection of iPS‐derived and
primary RPE cells
iPS‐derived RPE cells were transfected using Lipofectamine Stem
(Thermo Fisher Scientific) at Day 3 post‐seeding according to the
manufacturer's instructions. For each transfection in a 96‐well, 0.4 μg
plasmid was diluted in 5 μl Opti‐MEM I reduced serum medium
(Thermo Fisher Scientific), and then combined with 0.9 μl Lipofecta-
mine pre‐diluted in 5 μL Opti‐MEM medium. The Lipofectamine/DNA
mixture was allowed to stand at room temperature for 10min before
being added to the culture well. Cells were maintained at 37°C under
5% CO2 with transfection complexes removed 24 h post‐transfection.
Primary RPE cells were transfected using a P3 Primary Cell 96‐well
Nucleofector system (Lonza) at ~90% culture confluency on the second
passage according to the manufacturer's instructions. Briefly, 3 × 105
cells were electroporated with 0.72 μg DNA using program EA‐104 and
immediately diluted with 80 μl serum‐supplemented culture media.
25 μl of the diluted reaction was transferred to a 96‐well plate
containing 175 μl pre‐warmed serum‐supplemented culture media.
Transfected cells were cultured at 37°C under 5% CO2 for 24 h
followed by maintenance in serum‐free media.
2.6 | Measurement of recombinant GFP
expression in vitro
GFP expression in differentiated iPS‐derived RPE cells (Day 28) and
primary RPE cells (Day 14) was quantified using a SpectraMax iD5
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microplate reader (Molecular Devices). Cells were rinsed and culture
media was replaced with Dulbecco's phosphate‐buffered saline
(DPBS; Sigma) before fluorescence read (excitation: 485 nm, emis-
sion: 535 nm). GFP was visualized by fluorescence microscopy using
Olympus IX73 microscope (Olympus). Culture media was replaced
with DPBS before fluorescence imaging. To measure transfection
efficiency, cells (scaled‐up to a 48‐well plate) were trypsinized 48 h
posttransfection, rinsed with DPBS and analyzed using Attune
TABLE 1 DNA sequences of
RPE‐specific transcription factor
regulatory elements (TFREs) identified by
bioinformatic survey of retinal
endogenous promoters. Differing
nucleotides between endogenous and
consensus sequence are underlined.
Measurement of the TFRE relative ability
to activate transcription of recombinant
GFP genes in RPE cells is shown in
Figure 4. A BEST1 promoter sequence
map displaying the TFREs is shown in
Figure S1A
TFRE In BEST1 Endogenous sequence Consensus sequence
Overrepresented and common in at least 25%
AP‐2ε Y ACCCCTGAGGCCT TTGCCTGAGGCGA
ZNF300 N CGCCCCAG (endogenous)
MafA N GGCGGGGACAGCA GGCGGAGTCAGCA
ZNF35 N GCCGGGAAGACC (endogenous)
ChREBP:Mlx Ya CACGTGGTCCCCAGGTG CACGTGGCAAGCACGTG
Overrepresented
SPZ1 Y TGGAGGGTGTT (endogenous)
EKLF Y CAGGTGGGGTT CCGGTAGGGTG
ZBTB7 Y CAGCCCCCTAACC AGCCCCCCAAAAA
NF‐κB Y TGGGAATTTCAT CGGGACTTTCCA
Zic2 Y CTCAGCATGTG CACAGCAGGAG
HRE Ya GGACGTGCC (endogenous)
c‐Myb Y CAACAGTCCT CAACCGCCAT
MYRF Y CTGTGCCAGGAA (endogenous)
SALL2 N TCGGGTGGGTT (endogenous)
HELT Y GCCCACGTGAGT GGGCACGTGACC
Common in at least 25%
AML3 Y AGCAGTGGTTCTTG AGCTGTGGTTTGTG
DICE Y TGCTCTCTTCATTG TGTTCTCTCCACAG
AREB6 Y AGGTTTCAG (endogenous)
IR1 nGRE Y CCTTCCTGGAGAGT GCCTCCTGGAGAGG
MafF Y AGTGCTGAGCCGCCGTC ACTGCTGAGTCAGCAAT
MGA Y CGGGGTCACCACACACA AGGTGTGACTTCACACC
NF‐κB (p50) Y AGGGAGTCCC GGGGATTCCC
C/EBPε:ATF4 Y TGAAGCAA (endogenous)
AP‐4 Y CACCAGCTGCC (endogenous)
Lf Y GGCACTGGC GGCACTTGC
Literature
Otx2 Y TCCCTAAGCCAGGA CAATTAATCCCTAC
SIX3 Y TCTTGTAATCTGCTCAGAA ATGTGTAATGACTTCACTC
PAX6 Y TAAATTCCAGCCCTG TTAGTTCCAGGTCAG
MITF Ya (HELT) GTCACGTGAC
Abbreviations: AML3, runt‐related transcription factor 2/CBFA1; AP‐2ε, activator protein 2 epsilon;
AP‐4, activating enhancer binding protein 4; AREB6, Atp1a1 regulatory element binding factor 6; C/
EBPε:ATF4, heterodimer of C/EBP epsilon and ATF4; ChREBP:Mlx, heterodimer of ChREBP and Mlx;
c‐Myb, cellular myoblastosis virus oncogene v‐Myb; DICE, downstream immunoglobulin control
element; EKLF, erythroid krueppel like factor; HELT, hey‐like bHLH‐transcription factor; HRE,
hypoxia‐response element; IR1 nGRE, binding site for glucocorticoid receptor; Lf, lactotransferrin and
delta‐lactoferrin; MafA, lens‐specific Maf/MafA‐sites; MafF, transcription factor MafF; MGA, MAX
gene associated; MITF, microphthalmia transcription factor; MYRF, myelin regulatory factor; NF‐κB
(p50), nuclear factor‐κB p50 subunit; NF‐κB, nuclear factor κB; Otx2, orthodenticle homeobox 2;
PAX6, PAX6 paired domain and homeodomain; SALL2, zinc finger protein Spalt‐2, sal‐like 2; SIX3,
SIX3/SIX domain and homeodomain; SPZ1, spermatogenic Zip 1; ZBTB7, zinc finger and BTB domain
containing 7; Zic2, Zic family member 2; ZNF300, KRAB‐containing zinc finger protein 300; ZNF35,
zinc finger protein ZNF35.
aOverlap with HELT in BEST1 promoter (endogenous sequence from another promoter was used if
available).
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Acoustic Focusing Cytometer (Thermo Fisher Scientific). Background
fluorescence/absorbance was determined in cells transfected with a
promoterless vector.
3 | RESULTS
3.1 | Bioinformatic identification of TFREs in
endogenous RPE gene promoters
We previously devised a methodical, comprehensive approach for
bioprocess‐directed design of synthetic promoters based on genomic
sequence information (Johari et al., 2019). The work flow enables
identification of TFREs associated with endogenous gene promoters
with specific characteristics, thus allowing de novo design of syn-
thetic promoters with relevant functional features. In this study, we
hypothesized that it was feasible to construct RPE‐specific pro-
moters using assemblies of the corresponding RPE‐specific TFREs
(summarized in Figure 1). To profile endogenous gene expression in
RPE and PR cells, we utilized transcriptomic datasets from Booij
et al. (2009, 2010). A subgroup of 35 highly expressed RPE‐specific
genes was created by selecting genes with a microarray expression
level > 6,000 units in RPE and at least four‐fold higher expression
levels in RPE than in PR cells (as well as choroids). As expected, the
BEST1 (VMD2) gene was highly and preferentially expressed in RPE
cells, confirming the potential use of its promoter to drive RPE‐
specific expression in vitro (Esumi et al., 2004) and in vivo (Guziewicz
et al., 2013; Kachi et al., 2006). A corresponding PR‐specific group
was created by selecting 35 genes with expression level < 6,000 units
in RPE and RPE/PR expression fold change of < 0.5, whereas a non-
specific group was created by selecting 35 genes with expression
level > 6,000 units and RPE/PR expression fold change of between
0.97 and 1.03. Table S1 lists the selected genes in each group.
For each selected gene, a transcriptional start site (TSS) was
obtained from the literature or the eukaryotic promoter database
(EPD; epd.epfl.ch), or if not available, was estimated based on an-
notated 5′UTR sequences. Relative to the TSS a −1000 to + 200 bp
(or the start codon) segment was extracted from the human genomic
sequences for putative TFRE analysis. TFRE identification was
performed using Genomatix Gene Regulation software using two
different analyses, (i) overrepresented TFREs in each group with
promoter Z‐score > 2.5 (against a human promoter background pre‐
defined by Genomatix), and (ii) common TFREs, that is, frequently
occurring elements in each group, set at ≥25% (9/35) of the genes.
The results revealed 132 and 383 discrete TFREs in RPE‐specific
groups using the overrepresented and common methods respec-
tively. To minimize false positives in the RPE‐specific group, we fil-
tered out TFREs that also occurred in the PR/nonspecific group
(Figure 2) as well as common TFREs that did not occur in BEST1
promoter. To increase the TFRE pool complexity, we selected only up
to 2 TFREs with the highest Z‐scores from each TF family. 4 TFREs
namely Otx2, SIX3, PAX6, and MITF that are required to induce iPS
cells to RPE (D'Alessio et al., 2015; Kokkinaki et al., 2011; not se-
lected by the bioinformatic analysis due to the high selection strin-
gency) and present in BEST1 promoter (see Figure S1A) were also
included. We note that in our analysis MITF was identified only in
BEST1 promoter and the primary site overlapped HELT (Esumi
et al., 2004, 2007). Table 1 lists the final set of 29 TFREs in-
corporated into the functional screen and their endogenous and
consensus sequences (derived from the endogenous promoters and
Genomatix software, respectively). The TF matrix/family, frequency
and Z‐score/p‐value of the selected TFREs are detailed in Table S3.
To further analyze the “transcriptional landscape” of RPE cells
and identify active TFs contained within, we surveyed putative
TFREs in hCMV‐IE1. Using Genomatix MatInspector tool, 70 discrete
TF families were identified in the CMV promoter. A subset of 10 TFs
TABLE 2 Transcription factor
regulatory elements (TFREs) identified by
bioinformatic survey of cytomegalovirus
(CMV) promoter and their
overrepresentation in the retinal pigment
epithelium (RPE)‐specific, photoreceptor
(PR)‐specific, and nonspecific groups.
Known transcriptional repressors (YY1
and Gfi1) are excluded from analysis.
Measurement of the TFRE relative ability
to activate transcription of recombinant
photoreceptor (GFP) genes in RPE cells is
shown in Figure 4b. A CMV promoter
sequence map displaying the TFREs is










Sp1 6 TGGGGCGGAGT N Y Y Y
CREB 6 ATTGACGTCAATG Y N Y Y
NF‐κB 4 (consensus) Y Y N N
NF1 4 TTGGCAGTACATCAA Y N N Y
TLX1 3 CGGTAAATGG N N N Y
RAR 3 TGCCCAGTACATGACCT N N N N
C/EBPε 2 TGTCGTAAC (C/EBPε:ATF4) Y Y N N
AhR/ARNT 2 TGGGCGTGGATA N Y N Y
AP‐1 2 CGTGAGTCAAA N N N N
SRF 1 CCATATATGGA Y N N Y
Abbreviations: AhR/ARNT, aryl hydrocarbon receptor and nuclear translocator heterodimer; AP‐1,
activator protein 1; C/EBPε, CCAAT/enhancer binding protein epsilon; CREB, cAMP‐responsive
element binding protein; NF1, nuclear factor 1; NF‐κB, nuclear factor‐κB; RAR, retinoic acid receptor;
Sp1, stimulating protein 1; SRF, serum response factor; TLX1, T‐cell leukemia homeobox 1.
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that are known to be positive regulators of CMV activity in different
cell types (e.g., Brown et al., 2015; Ghazal et al., 1992; Lashmit
et al., 2009) were selected for screening (Figure S1B). To further
minimize this pool (design space) as well as false positives, we se-
lected TFRE sequences with the highest Genomatix matrix similarity
from each TF family as summarized in Table 2. The TF matrix/family,
frequency and matrix similarity of the selected TFREs are detailed in
Table S4. We note that viral‐derived NF‐κB sequence is identical to
the consensus sequence (Table 1).
3.2 | Determination of TFRE activity in RPE cells
Previous studies showed that iPS‐derived RPE cells exhibit mem-
brane potential, ion transport, polarized vascular endothelial growth
factor secretion, and gene expression profile that closely resemble to
those of native human RPE (Kokkinaki et al., 2011; Liao et al., 2010).
To compare the utility of different RPE models in constructing and
evaluating RPE promoters, we utilized iPS‐derived human RPE cells
(iCell® RPE, FujiFilm Cellular Dynamics) and primary human fetal
TABLE 3 Composition of specific
transcription factor regulatory
element (TFRE) copies in first‐generation
synthetic promoters
TFRE 1/01 1/02 1/03 1/04 1/05 1/06 1/07 1/08 1/09 1/10 1/11
Endogenous




ChREBP:Mlx 7 4 4 2
SPZ1 4 4 2
EKLF 4 4
ZBTB7 4 4 2
NF‐κB 4 4 2
Zic2 4 4 2
HRE 7 4 4 2
c‐Myb 4 4 2
MYRF 4 4 2
SALL2 4 4
HELT/MITF 7 6 6 6 6 6 6 6 6 6 2
AML3 4 4
DICE 4 4
AREB6 4 4 2
IR1 nGRE 4 4 2
MafF 4 4 2
MGA 4 4 2
NF‐κB (p50) 4 4
C/EBPε:ATF4 4 4 2
AP‐4 4 4 2
Lf 7 4 4 2
Otx2 4 4 2
SIX3 4 4 2
PAX6 4 4 2
Total copies 28 30 30 30 30 30 30 30 30 30 40
Abbreviations: AML3, runt‐related transcription factor 2/CBFA1; AP‐2ε, activator protein 2 epsilon;
AP‐4, activating enhancer binding protein 4; AREB6, Atp1a1 regulatory element binding factor 6;
C/EBPε:ATF4, heterodimer of C/EBP epsilon and ATF4; ChREBP:Mlx, heterodimer of ChREBP and
Mlx; c‐Myb, cellular myoblastosis virus oncogene v‐Myb; DICE, downstream immunoglobulin control
element; EKLF, erythroid krueppel like factor; HELT, hey‐like bHLH‐transcription factor; HRE,
hypoxia‐response element; IR1 nGRE, binding site for glucocorticoid receptor; Lf, lactotransferrin and
delta‐lactoferrin; MafA, lens‐specific Maf/MafA‐sites; MafF, transcription factor MafF; MGA, MAX
gene associated; MITF, microphthalmia transcription factor; MYRF, myelin regulatory factor; NF‐κB,
nuclear factor κB; NF‐κB (p50), nuclear factor‐κB p50 subunit; Otx2, orthodenticle homeobox 2;
PAX6, PAX6 paired domain and homeodomain; SALL2, zinc finger protein Spalt‐2, sal‐like 2; SIX3,
SIX3/SIX domain and homeodomain; SPZ1, spermatogenic Zip 1; ZBTB7, zinc finger and BTB domain
containing 7; Zic2, Zic family member 2; ZNF300, KRAB‐containing zinc finger protein 300; ZNF35,
zinc finger protein ZNF35.
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RPE cells (Clonetics® RPE, Lonza). Both culture models developed
into monolayers with tight junctions with iPS‐derived RPE cells ex-
hibited obvious pigmentation as well as more uniform in size and
shape (Figure 3). We note that there were no established cells
representative of PRs that could be utilized as control cells
(McDougald et al., 2019). The relative transcriptional activity of each
TFRE (Tables 1 and 2) in RPE cells was determined as previously
described (Johari et al., 2019) using a GFP reporter construct that
contained seven repeat copies of a specific TFRE in series, upstream
of a minimal mammalian core promoter (hCMV‐EI core containing a
TATA box and an Inr motif, ‒34 to +50 relative to the TSS). A control
CMV promoter‐reporter plasmid was constructed using the hCMV‐
IE1 promoter (‒600 to +50 relative to the TSS, i.e., the complete
hCMV‐IE1 enhancer containing the distal, proximal and core pro-
moter regions, henceforth referred to as CMV) upstream of the
GFP ORF.
Optimized transient transfection of plasmid DNA into iPS‐
derived RPE by lipofection and primary RPE by nucleofection yielded
transfection efficiencies of ~71% and ~85%, respectively at 48 h
posttransfection (measured using a vector harboring a full‐length
CMV promoter, flow cytometry data not shown). Measurement of
GFP expression deriving from transfection of each endogenous se-
quence TFRE‐reporter plasmid in mature RPE cells is shown in
Figure 4a (normalized to expression derived from CMV). This ana-
lysis identified four TFREs that significantly increased expression
over basal expression from the minimal core promoter (2.6%–10.9%
CMV, p < 0.001), that is, ChREBP:Mlx, HRE, HELT/MITF, and Lf. Two
elements (ChREBP:Mlx and HELT/MITF) mediated different levels of
GFP expression in the iPS‐derived and primary cells, likely due to
differences in TF relative abundance. As the relative level of reporter
expression is also a function of affinity of the TF for its cognate TFRE
we tested the consensus binding sequence of the TFREs (Table 1), as
well as viral‐derived TFREs (Table 2) to further identify elements
that can independently mediate activation of gene transcription
using available TFs in RPE cells. This analysis (Figure 4b) showed that
NF‐κB consensus sequence and viral‐derived CREB were highly
TABLE 4 Composition of specific TFRE copies in second‐generation synthetic promoters
TFRE 2/01 2/02 2/03 2/04 2/05 2/06 2/07 2/08 2/09 2/10 2/11 2/12 2/13
Endogenous
AP‐2ε 1 2 2 2 1 2 1
ChREBP:Mlx 1 2 4 2 2 1 2 2 1 2 1
SPZ1 1 2 2 2 1 2 1
Zic2 1 2 2 2 1 2 1
HRE 7 7 2 4 2 7 6 6 2 4 6 6 6
c‐Myb 1 2 2 2 1 2 1
MYRF 1 2 2 2 1 2 1
HELT/MITF 7 7 2 4 2 7 6 6 2 4 6 6 6
IR1 nGRE 1 2 2 2 1 2 1
MGA 1 2 2 2 1 2 1
C/EBPε:ATF4 1 2 2
Lf 7 7 2 4 2 7 4 6 2 4 5 5 5
Otx2 1 2 2 2 1 2 1
Consensus
MafF 1 2 2 2 3 1 2 1
NF‐κB 2 7 7 6 2 4 7 7 7
PAX6 2
Viral
Sp1 2 2 2 3 3
CREB 2 4 7 7 7
C/EBPε:ATF4 2 1 2 2 2 2 2
AP‐1 3 2
Total copies 21 32 28 36 30 28 28 35 34 35 36 41 41
Size (bp) 323 478 468 570 498 414 430 525 548 538 526 602 552
Abbreviations: AP‐1, activator protein 1; AP‐2ε, activator protein 2 epsilon; C/EBPε:ATF4, heterodimer of C/EBP epsilon and ATF4; ChREBP:Mlx,
heterodimer of ChREBP and Mlx; c‐Myb, cellular myoblastosis virus oncogene v‐Myb; CREB, cAMP‐responsive element binding protein; HELT,
hey‐like bHLH‐transcription factor; HRE, hypoxia‐response element; IR1 nGRE, binding site for glucocorticoid receptor; Lf, lactotransferrin and
delta‐lactoferrin; MafA, lens‐specific Maf/MafA‐sites; MafF, transcription factor MafF; MGA, MAX gene associated; MITF, microphthalmia transcription
factor; MYRF, myelin regulatory factor; Otx2, orthodenticle homeobox 2; PAX6, PAX6 paired domain and homeodomain; Sp1, stimulating protein 1;
SPZ1, spermatogenic Zip 1; Zic2, Zic family member 2.
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F IGURE 1 Summary of bioinformatic analysis (Steps 1–3) followed by in vitro screening of transcription factor regulatory elements (Step 4)
and characterization of heterotypic constructs (Step 5) for de novo design of retinal pigment epithelial (RPE) synthetic promoters or
engineering of endogenous RPE promoters
F IGURE 2 Distribution of discrete transcription factor regulatory elements (TFREs) across retinal pigment epithelium (RPE)‐specific,
photoreceptor (PR)‐specific and nonspecific groups. Retinal endogenous promoters mediating high endogenous gene expression in RPE cells, PR
cells, and both RPE and PR cells (35 promoters in each group; Table S1) were surveyed for the presence of discrete TFREs using Genomatix
Gene Regulation software using (a) overrepresented TFRE method by analyzing the promoters against a pre‐defined human promoter
background, and (b) common TFRE method by selecting TFREs that present in at least 25% (9/35) of the genes. The region −1000 to +200
relative to putative transcriptional start site (TSS) was analyzed against a human promoter background to find overrepresented TFREs in each
group, or for common TFREs that present in at least 25% (9/35) of the promoters. To identify potentially active TFREs in the high activity group,
TFREs that also occurred in the PR and/or nonspecific groups were excluded and (c) the remaining TFREs from both methods were narrowed
down to 25 as described in text. DNA sequences of the 29 selected TFREs (including 4 from the literature) are listed in Table 1
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active, attaining up to 36% of CMV activity. Consensus NF‐κB (p50),
MafF, and PAX6 also displayed substantial activities (2.4%–8.5%
CMV, p < 0.001) although we suspect the former was contributed by
a weak binding of NF‐κB (V$NFKAPPAB.02 matrix similarity 0.868).
Contrarily, an alteration of six nucleotides flanking the E‐box
(CACGTG) in HELT/MITF endogenous sequence into discrete HELT
and MITF consensus sequences resulted in 29%–68% reduction in
GFP expression, while the use of an Lf consensus sequence dimin-
ished its activity. Furthermore, viral‐derived Sp1, C/EBPε:AT4, and
AP‐1 demonstrated low, but significant activities (>2.0% CMV,
p < 0.01). Other TFREs showed no observable increase in GFP above
core control levels, suggesting discrete mechanisms of TFRE
transcriptional activation or absence of their cognate TFs.
As TF abundance may also impact cell specificity, we further
analyzed TF expression at the transcript level using the Booij
et al. (2009, 2010) datasets. While this does not permit direct
quantification of TF activity in PR, it does provide information on
general TF expression patterns between RPE and PR cells (mRNA
half‐lives in two different cell types can be expected to be compar-
able; see Johari et al., 2019), enabling prediction of cell‐type speci-
ficity. Furthermore, this method is easily applicable to promoter
design for most human cell types, for which transcriptomic datasets
are normally accessible. Analysis of the mRNA transcript data
(Table S2) indicate that MITF and C/EBPα,β,δ,ε were highly specific
to RPE (3.87‒10.7‐fold change RPE/PR). While the former has been
widely reported to be a key TF regulator of RPE cells (e.g., Esumi
et al., 2007), this data indicates that C/EBP could be utilized as an
RPE‐specific element. Lf, AP‐1, and MafF (2.31–2.82‐fold change),
and to a lesser extent C/EBPγ, AhR, NF‐κB, Mlx, and PAX6
(1.21–1.75‐fold change), were also expressed at relatively higher
levels in RPE cells. On the other hand, Sp1 was expressed in RPE and
PR cells at the same level (1.10‐fold change) whereas CREB was
expressed slightly higher in PR (0.82‐fold change) — consistent with
the bioinformatic analysis of the RPE and PR‐specific groups
(Table 2). We further note that Sp1 (V$SP1.01) was the most com-
mon element in both RPE and PR‐specific groups with 115 binding
sites in 31/35 RPE promoters and 115 binding sites in 22/35 PR
promoters, respectively (data not shown). In summary, these data
identify a group of transcriptionally active TFRE sequences that can
be utilized to construct synthetic promoters for RPE cells. Contra-
riwise, the data indirectly serves as a reference of TFREs that should
be avoided for the construction of PR‐specific promoters.
3.3 | First generation RPE promoters enable
identification of repressor elements in RPE cells
Given the above finding that HELT/MITF could bind to suboptimal
E‐box sequences (leading to lower activities), we utilized the four
positive endogenous TFREs identified in the screening exercise to
evaluate their compatibility in a heterotypic construct (promoter
1/01). Importantly, given that a TF can act as a transcriptional
activator or repressor (or both), we designed a set of promoters
(promoter 1/02–1/10) containing specific combinations of the en-
dogenous TFREs selected in the bioinformatic analysis to assess
elements that primarily function as repressors in RPE cells. For each
promoter, 6 copies of HELT/MITF were included to provide a pro-
moter basal expression, and the other 27 specific TFREs (4 copies
each) were randomly distributed using R software with the following
design rules: (i) each specific TFRE occurred twice in different pro-
moters, (ii) no two specific TFREs re‐occurred in another promoter,
and (iii) the relative order of constituent TFREs was random, sepa-
rated by minimal spacers (Brown et al., 2017; Johari et al., 2019).
Additionally, to test whether the selected endogenous elements from
the bioinformatics analysis could generally act as positive effectors in
heterotypic constructs, we constructed a promoter (1/11) containing
two repeat copies of each element that present in upstream of
BEST1 promoter (–900 to –1 relative to the TSS). The synthetic
promoter constructs were chemically synthesized and inserted up-
stream of the minimal CMV core promoter in GFP reporter plasmids.
An endogenous BEST1 promoter (‒585 to +76 relative to the TSS;
Esumi et al., 2004) was used as an RPE‐specific control, which in our
study exhibited ~1.5%–2% relative activity compared to the ubiqui-
tous CMV promoter (representative GFP fluorescence images are
shown in Figure S2). We note that we observed insignificant GFP
expression (≲0.5% CMV) using an endogenous RPE65 promoter
F IGURE 3 Epithelial morphology in
differentiated human retinal pigment epithelial
(RPE) cell monolayers. Microscope visualization
of (a) induced pluripotent stem (iPS)‐derived RPE
cells at Day 28 and (b) primary RPE cells at Day
14 post‐plating provides evidence of polygonal
morphology and pigmentation. Images were
taken with a 10× objective
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(–655 to +52 relative to the TSS; Boulanger et al., 2000; Kachi
et al., 2006).
The GFP expression for the first library of synthetic promoters
(Table 3) are shown in Figure 5a. Promoter 1/01, which contained all
four active TFREs identified in the screening exercise, did not display
improved activity (<10% CMV) compared to testing of independent
TFREs in homotypic constructs (Figure 4a). We surmise that HELT/
MITF TF was constitutively bound to ChREBP:Mlx E‐box sequence
with lower transcriptional activation as observed in the HELT and
MITF consensus sequences (Figure 4b), thus lowering the promoter's
activity. Further, the data in Figure 5a demonstrated that active
HELT/MITF in promoters 1/02‒1/10 were counteracted by re-
pressor elements to produce weak or nonfunctional promoters. To
identify these repressor elements, the synthetic promoters’ activities
were analyzed against their individual components. This breakdown
(Figure 5b) suggests that seven elements, that is, ZNF300, ZBTB7,
NF‐κB, AML3, NF‐κB (p50), SIX3, PAX6 had repressive effects on
transcriptional activity, where the promoters exhibited < 2% fluor-
escence level in both iPS‐derived and primary RPE cells. With the
exception of NF‐κB and PAX6, this finding is consistent with the
literature indicating that these TFREs function as transcriptional
repressors in mammalian cells (Costoya, 2007; Gou et al., 2004;
Guan et al., 2005; Isenmann et al., 2007; Liu et al., 2010).
Further bioinformatic examination on the endogenous NF‐κB
sequence (V$NFKAPPAB.02, matrix similarity 0.869) indicated that
this particular sequence overlapped with transcriptional repressor
RBP‐Jκ binding sequence (V$RBPJK.02 matrix similarity 0.958;
Figure S1A). This constitutive binding by RBP‐Jκ (Lee et al., 2000)
expounds the repression observed in promoters 1/03 and 1/04
(Figure 5) as well as the inactivity of endogenous NF‐κB sequence
F IGURE 4 Screening discrete transcription
factor regulatory element (TFRE) activity in
retinal pigment epithelial (RPE) cell models.
Seven copies of each TFRE (as described in
Tables 1 and 2) comprising (a) endogenous
sequences and (b) consensus/viral sequences
were cloned in series upstream of a minimal
cytomegalovirus (CMV) core promoter in
reporter vectors encoding green fluorescent
protein (GFP). 5 × 104 iPS‐derived RPE cells were
plated and 0.4 μg of plasmid was transfected into
the cells by lipofection at Day 3 post‐plating.
0.72 μg of plasmid was transfected into 3 × 105
primary RPE cells by nucleofection followed by
plating. GFP fluorescence level was measured in
the fully differentiated iPS‐derived and primary
RPE cells at Day 28 and Day 14 post‐plating,
respectively. Data are expressed as a percentage
with respect to the GFP expression of a vector
containing CMV‐IE promoter. Data shown are the
mean value ± standard deviation of three
independent experiments each performed in
triplicate
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compared to the consensus sequence (Figure 4). In contrast, PAX6
has been reported to act as a transactivator in RPE cells (Raviv
et al., 2014) and its consensus sequence displayed significant activity
(Figure 4b). Thus, PAX6 may be excluded as a repressor in which the
repression observed in promoters 1/04 and 1/09 could be attributed
to RBP‐Jκ and NF‐κB (p50) elements respectively. Further, as pro-
moter 1/02 exhibited lower GFP expression in primary cells com-
pared to promoters 1/01 and 1/05 and did not contain any of above
repressor elements, we deduce that the AREB6 secondary binding
sequence employed repressed transcription as reported by Ikeda and
Kawakami (1995) with E‐box motif in HELT/MITF sequence acted as
the main binding site of multi‐domain AREB6 protein (see
Figure S1A). Promoter 1/11, which contained two copies of selected
elements from the BEST1 promoter demonstrated ~3–4‐fold higher
expression than the BEST1 promoter itself, confirming the utility of
the RPE cell synthetic promoter design approach.
3.4 | Second generation RPE promoters exhibit an
inverse correlation between activity and specificity
Based on the observations from the first library, we created a second
library of functional synthetic promoters (Table 4) by omitting
probable repressor elements with two objectives: (i) high RPE
cell‐specificity, attainable by limiting the constructs to endogenous
elements (promoters 2/01–2/07), and (ii) high RPE transcriptional
activity, attainable by including active viral‐derived elements (pro-
moters 2/08–2/13). The former is highly desirable for targeted AAV‐
mediated transduction in vivo, whereas the latter can be efficiently
applied for recombinant protein expression in vitro to investigate the
effects of protein overexpression in retinal diseases (e.g., HtrA1
enrichment; Melo et al., 2018) as well as to reprogram RPE cells to an
altered lineage (e.g., neuronal cells; Hu et al., 2014). Additionally, we
created an engineered BEST1 promoter by mutating a total of 25
nucleotides to remove repressors and/or introduce active TFREs
(Figure S3).
Measurement of GFP expression after transfection into RPE
cells is shown in Figure 6. These data show that promoter activities
vary by ~30‐fold, where the most active promoters exceeded the
transcriptional activity of CMV in primary cells. The engineered
BEST1 promoter exhibited a 30%–32% improvement in expression
compared to its native counterpart, although this was largely insig-
nificant (p = 0.10–0.14). Similarly, promoter 2/03, devoid of repressor
elements, displayed a 2.1‐fold increase in expression compared to
promoter 1/11 in primary cells, although biasing the elements to-
wards active elements (promoter 2/04) appeared to have a negative
effect — likely due to suboptimal TFRE stoichiometry (Martinelli &
De Simone, 2005). Anticipated to be RPE‐specific, the in vitro ex-
pression levels obtained from promoters 2/01–2/05 were up to ~8‐
fold higher than that of BEST promoter but significantly lower
compared to CMV (≤17%). While NF‐κB in promoters 2/06 and 2/07
significantly improved expression with the latter attaining 62% CMV
activity in primary cells, we conjecture the use of high copy number
of NF‐κB would increase promoter activity in PR (and other) cells,
where the cognate TF is also present (Table S2). Expectedly, the data
in Figure 6 also shows that strong RPE promoters can be constructed
by incorporating viral‐derived CREB, Sp1 and AP‐1, and biasing the
TFRE copy number towards highly active elements resulted in
F IGURE 5 Measurement of first‐generation synthetic promoter activity in retinal pigment epithelium (RPE) cells. (a) 11 synthetic
promoters comprising Library 1 (transcription factor regulatory element [TFRE] compositions described in Table 3) were transfected into
induced pluripotent stem (iPS)‐derived and primary RPE cells. Intracellular green fluorescent protein (GFP) level was analyzed in differentiated
RPE cells. Data are expressed as a percentage with respect to the expression level exhibited by the control cytomegalovirus (CMV) promoter.
GFP expression driven by the BEST1 promoter was also tested as RPE‐specific promoter control. Data shown are the mean ± standard
deviation of three independent experiments each performed in triplicate. (b) The GFP levels exhibited by the synthetic promoters in (a) were
plotted against the promoters’ specific TFRE components to identify potential repressor elements (marked by an asterisk [*]) by setting the
minimum expression threshold to 2% CMV and further analyzed as described in the text
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substantial increase in promoter strength up to 109% of CMV in
primary cells. However, reporter expression in iPS‐derived cells was
relatively lower compared to that observed for the primary cells
(achieving only ~50% of CMV activity), indicative of differences in
transcriptional landscape. We deduce that iPS‐derived cells, repro-
gramed from somatic (skin or blood) cells, contained untested TFs
that conferred relatively higher CMV expression.
To further illustrate the promoters’ (predictive) capability in
conferring specific and exclusive cellular tropism for RPE gene
therapy, we calculated an “estimated RPE/PR specificity ratio” for
each promoter as a function of (i) the transcriptional activity of a
specific TFRE (Figure 4), (ii) the copy number of a specific TFRE
within the promoter (Table 4), and (iii) the cognate TF mRNA ex-
pression fold‐change in RPE over PR (Table S2; Equation 1). As
shown in Figure 6, this analysis indicates that promoters designed
with endogenous elements would drive targeted transgene expres-
sion to the RPE cells in vivo, whereas promoters with viral‐derived
elements would have significantly reduced specificity. While not di-
rectly relevant, our data from a separate study showed that these
promoters exhibited no or very low activity (≤20% CMV) in a human
kidney cell line (Figure S4), illustrating that cell‐specific control of
recombinant gene transcriptional activity is feasible. Furthermore,
one major limitation of AAVs as vectors is that AAV packaging
capacity is fundamentally restricted to 5 kb where packaged vector
genomes derived from plasmid‐encoded vectors exceeding 5 kb are
truncated on the 5′ end and heterogeneous in length, as well as
result in a considerable reduction in viral production yields (Wu
et al., 2010). The synthetic promoters in this study were relatively
small in size compared the control BEST1 and CMV promoters
(Table 4), making them advantageous for AAV‐mediated gene de-
livery. For example, promoter 2/03 achieved a 4.9−6.8‐fold increase
in transcriptional activity over the BEST1 promoter while being 29%
shorter in length at 468 bp. We anticipate that combinatorial,
context‐dependent empirical modeling (Johari et al., 2019) will
further assist the construction of promoters with optimal TFRE
stoichiometry for RPE gene therapy applications.
4 | DISCUSSION
In this study we have characterized various regulatory elements in
RPE cells derived from endogenous and viral promoters. Using a
combined in silico and in vitro screening approach, we successfully
identified active TFRE candidates (sequences) that could be utilized
to construct synthetic promoter assemblies with strong and/or RPE
specific expression. The data in this study also indirectly serves as a
reference for TFREs that should be avoided in constructing
PR‐specific promoters. Furthermore, although our specific objective
was to identify active RPE‐associated regulatory elements, it should
be recognized that this approach may be universally applicable and
adapted to accommodate screening of TFREs associated with other
cell/tissue types. Indeed, cell function is largely controlled by the
action of TFs that recognize and bind particular sequence motifs in
the genome and regulate gene expression. While hundreds of TFs are
expressed in any one tissue type (Vaquerizas et al., 2009), only a
small range of core TFs are responsible in programming the gene
expression that define individual cell identity (D'Alessio et al., 2015).
This is evident, for example, where our study indicated that SRF
(serum response factor) element had no transcriptional activity in
RPE cells (Figure 4b) yet the identical sequence formed the primary
building block of synthetic promoters that conferred muscle‐specific
expression (Li et al., 1999).
We further identified suboptimal TF binding sequences and en-
dogenous TFREs (25%) that acted as transcriptional repressors.
These were not entirely unexpected as the promoters in RPE have
evolved to function in a complex spatiotemporal gene regulation of
the retina including pigment biogenesis, ion transport, and growth
factor secretion (Booij et al., 2010). However, it is highly unlikely that
they will be optimal for use in a more specific context such as AAV‐
mediated gene therapy. For example, many of the transcriptional
repressors identified in this study are present in BEST1 promoter
suggesting that a large proportion of the BEST1 sequence (and that
of other RPE promoters) may be functionally redundant for re-
combinant gene expression. Thus, identification of such repressor
F IGURE 6 Measurement of second‐generation synthetic
promoter activity and predicted retinal pigment epithelium (RPE) cell
specificity. 13 synthetic promoters comprising Library 2
(transcription factor regulatory element [TFRE] compositions
described in Table 4) were transfected into induced pluripotent stem
(iPS)‐derived and primary RPE cells. An engineered BEST1 promoter
(E.BEST1) was constructed by mutating a total of 25 nucleotides to
remove and/or introduce specific TFREs (Figure S3). Intracellular
green fluorescent protein (GFP) level was analyzed in differentiated
RPE cells. Data are expressed as a percentage with respect to the
expression level exhibited by the control cytomegalovirus (CMV)
promoter. Predictive RPE/photoreceptor (PR) specificity ratio of
each promoter was calculated using Equation 1 based on the
transcriptional activity of a specific TFRE, the copy number of a
specific TFRE in the promoter, and the cognate transcription factor
(TF) mRNA expression fold‐change in RPE/PR. Data are expressed as
a percentage with respect to the specificity ratio of the control
bestrophin‐1 (BEST1) promoter
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elements, as well as optimization of active TF binding sequences,
would permit engineering of endogenous promoters for enhanced
performance. With regard to the latter, tens of TFRE motif sequence
variants can be characterized simultaneously through in vitro use of
parallel high‐throughput screening techniques, allowing determina-
tion of their optimal binding affinity. With regard to the former, the
functional impact of repressor elements can be identified and accu-
rately quantitated using the TFRE‐specific decoy technology pre-
viously developed in this laboratory (Brown et al., 2013, 2015).
Even though we have not tested our promoters against PR (due
to lack of reliable model cells, see below), and therefore cannot de-
finitively claim that they will exhibit restricted gene expression in
RPE cells, the methodology presented allows creation of promoters
using binding sequences that are exclusive to RPE‐specific promoters
and correspond to relatively high expression of their cognate TFs in
RPE cells, thus enabling confident prediction of their functionality.
On the other hand, TATA box (present in the minimal core promoter)
is a known modular component in that the strength of the TATA‐
RNA polymerase complex and the ensuing transcription that it
mediates has very little noise to promoter activity—it simply acts as a
linear amplifier without influencing specificity of gene expression
controlled by upstream cis‐regulatory elements (Mogno et al., 2010).
Indeed, muscle (Li et al., 1999), deregulated β‐catenin (Lipinski
et al., 2004), liver (Han et al., 2011), and colorectal cancer cell‐
specific (Roberts et al., 2017) synthetic promoters all contained a
TATA box. Furthermore, our bioinformatic analysis indicated that
Sp1 is highly prevalent in all three groups (RPE, PR, and nonspecific)
analyzed—in agreement with the notion that Sp1 is essential for
maintaining basal transcription of genes and protection of CpG is-
lands from de novo methylation (Samson & Wong, 2002). Accord-
ingly, we conjecture that Sp1 does not influence the specificity of a
promoter that is designed to mediate cell type specific expression.
We further acknowledge that the RPE cell models we employed may
contain small subsets cells in a variably differentiated state that have
a transcriptional landscape deviating from that of the fully differ-
entiated population. To characterize this further experiments utiliz-
ing multiplex flow cytometry to directly link markers of RPE
differentiation (e.g., Plaza Reyes et al., 2020) to synthetic promoter
mediated reporter gene expression would be possible.
Lastly, in vitro model cells may have an altered transcriptional
landscape compared to cells in vivo and may vary from one model to
another. Our study demonstrated that iPS‐derived and primary RPE
cells transactivated the same TFREs (albeit at different levels), con-
curring with previous reports that these cells displayed appropriate
levels of RPE gene expression compared to native tissue (Ablonczy
et al., 2011; Liao et al., 2010). In contrast, there are no established
model cells representative of pure human retinal PRs (McDougald
et al., 2019). Isolated primary PR cells, deprived of their extracellular
matrix and cellular contacts (RPE, retinal and choroidal blood supply,
etc), display rapid kinetics of degeneration (Fernandez‐Bueno
et al., 2012). While iPS cells can be dependably differentiated into
PR cells following a 60‐day induction regimen, rapid loss of
cells committed to a PR fate (rhodopsin, opsin) was observed at
Day 45‒60 (Mellough et al., 2012). On the other hand, 661W PR cell
line, derived from a mouse retinal tumor, expresses several markers of
cone PR cells but not of rod cells (Tan et al., 2004) and was also
reported to exhibit the properties of retinal ganglion cells (Sayyad
et al., 2017). Nevertheless, where reliable model cells are not available,
we demonstrated that it may possible to design cell‐specific promoters
in silico for in vivo applications. As the quality and volume of ‘omics
data continues to increase, and, given the progressive development of
TFRE database and informatic tools (e.g., Wu et al., 2019), we envisage
that synthetic promoters will facilitate advancement of the current
revolution in AAV‐mediated gene therapy.
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